Join the Abrysvo group to help and get support from people like you.
Abrysvo News
One Dose of RSV Vaccine May Shield Older People for Two Seasons
WEDNESDAY, Sept. 3, 2025 — A single dose of RSV vaccine might protect seniors for two cold and flu seasons in a row, a new study says. Vaccination reduced seniors’ risk of hospitalization by 58% dur...
Heart Patients Urged To Seek Vaccination For Common Infectious Diseases
WEDNESDAY, Aug. 27, 2025 — It is vital that people with heart disease get vaccinated against common infectious diseases like COVID-19, influenza and RSV, a new clinical guideline says. Vaccination c...
CDC Now Recommends RSV Vaccine for Some Adults 50+
MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and P...
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 – Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7...
72 Percent of Infants Immunized Against Respiratory Syncytial Virus
TUESDAY, May 6, 2025 – In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory syncytial virus (RSV)....
FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
MONDAY, Jan. 13, 2025 – The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy...
Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season
WEDNESDAY, Jan. 8, 2025 – Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online Jan. 8 in JAMA ...
FDA Medwatch Alert: FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy
ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc. and Arexvy (Respiratory...
Immunocompromised Have Heterogeneous Antibody Response to RSV Vaccines
TUESDAY, Jan. 7, 2025 – For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about 40 percent do not seroconvert, according to a...
Confidence in Vaccines Both Steady and Rising in U.S. Adults
THURSDAY, Jan. 2, 2025 -- Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by the American public, while confidence in other ...
Has RSV Vaccine Hesitancy Subsided?
FRIDAY, Dec. 27, 2024 – More Americans believe in the effectiveness of vaccines developed to protect newborns and seniors against respiratory syncytial virus (RSV). More than half of U.S. adults...
RSVpreF Vaccine Effective in Preventing Severe RSV in Older Adults
WEDNESDAY, Dec. 18, 2024 – Respiratory Syncytial Virus Prefusion F (RSVpreF) vaccination is effective against RSV-related lower respiratory tract disease (LRTD) among adults aged 60 years or older,...
RSV Burden Remains High in Young Children in the United States
WEDNESDAY, Dec. 11, 2024 – The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA...
COVID-19, Flu, RSV Vaccine Coverage Low for Nursing Home Residents
TUESDAY, Nov. 26, 2024 – COVID-19, influenza, and respiratory syncytial virus (RSV) vaccination coverage is low among nursing home residents early in the 2024 to 2025 season, according to research...
Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
WEDNESDAY, Nov. 20, 2024 – A number of adults with outpatient medically attended respiratory syncytial virus (MA-RSV) infection experience hospitalization within 28 days, with a higher proportion...